LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
15 Giugno 2022 - 2:30PM
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a
clinical-stage pharmaceutical company focused on developing and
commercializing cancer therapies, announced the appointment of
Professor René Bernards to its Board of Directors. Professor
Bernards will serve as an independent director.
Dr. John S. Kovach, Founder and Chief Executive
Officer of Lixte, commented, “We are very pleased to welcome
Professor Bernards to our Board of Directors and we look forward to
his insight and guidance, as well as benefiting from his extensive
experience in the development of effective anti-cancer drugs from
their earliest stages through clinical use. Professor Bernards is a
leader in the field of molecular carcinogenesis, working at the
Netherlands Cancer Institute in Amsterdam. His research focuses on
identifying effective new drug combinations, new drug targets, and
mechanisms of resistance to anti-cancer drugs. He has also
co-founded four biotechnology companies to bring his scientific
discoveries to clinical oncology practice.”
Dr. Kovach continued, “Professor Bernards has
received many awards recognizing his excellence in cancer research.
He is a member of the Royal Netherlands Academy of Sciences, an
International Honorary Member of the American Academy of Arts and
Sciences and an International member of the National Academy of
Sciences (USA). Additionally, he is a fellow of the American
Association for Cancer Research (AACR) and received the Princess
Takamatsu Memorial Lectureship at this year’s AACR annual
meeting where he presented new data on the unexpected
effectiveness of Lixte’s lead clinical compound, LB-100, when given
with a variety of standard and investigational anti-cancer
compounds that have only modest activity on their own.”
Dr, Kovach concluded, “We have no doubt that the
company will benefit from Professor Bernards’ experience in
anti-cancer drug development as Lixte proceeds with clinical
development of LB-100, its first-in-class protein phosphatase 2A
(PP2A) inhibitor.”
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. (Nasdaq:
LIXT), is a clinical-stage pharmaceutical company focused on new
targets for cancer drug development and developing and
commercializing cancer therapies. Major drivers of cancer are
defects in the switches that turn the biochemical pathways in cells
on or off. Most cancer research over the past 30 years has focused
on the “on” switches because the “off” switches, especially the
master “off” switch protein phosphatase (PP2A), were believed to
cause intolerable toxicity in patients. LIXTE has achieved a
breakthrough with its novel, first-in-class lead clinical compound
and PP2A inhibitor, LB-100, demonstrating that LB-100 is readily
tolerated in cancer patients at doses associated with anti-cancer
activity. Based on extensive published preclinical data
(see www.lixte.com), LB-100 has the potential to significantly
improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE’s new approach has no known competitors and
is covered by a comprehensive patent portfolio. Initial
proof-of-concept clinical trials are in progress.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at http://www.sec.gov/edgar.shtml.
Lixte Contact:info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024